Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth
August 06 2020 - 7:00AM
- Extension of collaboration between UTHealth and
Immatics until end of 2024 providing Immatics exclusive access to
state-of-the art cGMP manufacturing infrastructure at The Evelyn H.
Griffin Stem Cell Therapeutics Research Laboratory
- Collaboration ensures continued clinical batch supply
for all of Immatics’ ongoing and next Adoptive Cell Therapy (ACT)
clinical trials in US and Europe
Houston, Texas, August 6, 2020
– Immatics N.V. (NASDAQ: IMTX; “Immatics”), a
clinical-stage biopharmaceutical company active in the discovery
and development of T cell redirecting cancer immunotherapies, today
announced the extension of its cell therapy manufacturing
collaboration with The University of Texas Health Science Center at
Houston (UTHealth), in Houston, Texas. The continued collaboration
grants Immatics access to UTHealth’s state-of-the-art cGMP
manufacturing infrastructure at the Evelyn H. Griffin Stem Cell
Therapeutics Research Laboratory, enabling continued production and
supply of Immatics’ specialized, cell-based product candidates for
testing in multiple clinical trials. Maximum capacity of the
facility is anticipated at 48 ACTengine® T cell products per month.
The new agreement will run until the end of 2024. Under the
agreement, UTHealth will provide Immatics with exclusive access to
three cGMP suites and support areas for the manufacturing of
various Adoptive Cell Therapy (ACT) products. Therapeutic T cell
production will be carried out by Immatics’ manufacturing personnel
and will be supported by a UTHealth-Immatics joint quality
team.
Steffen Walter, Ph.D., Chief Technology Officer
at Immatics, commented: “During the last five years, we have
established a strong and productive partnership with UTHealth that
has enabled the initiation of four ongoing clinical trials. As we
remain focused on the development of our clinical pipeline, this
extension of our collaboration with UTHealth will fulfill Immatics’
manufacturing needs for our early-stage ACT clinical programs for
the next four years. Being able to rely on a partner with profound
cell therapy expertise who is familiar with our technologies and
can support cGMP cell therapy production is critical to ensuring
the advancement of our clinical trials. We look forward to
continuing this fruitful collaboration with the experts at
UTHealth.”
Fabio Triolo, D.d.R., M.Phil., Ph.D., The Clare
A. Glassell Distinguished Chair and Director of the Cellular
Therapy Core at UTHealth, added: “Signing the extended contract
with Immatics fits into our strategy at UTHealth of supporting the
development of new treatments for patients in need. We therefore
look forward to continuing our collaboration and further leveraging
the potential of our manufacturing capabilities.”
About Immatics’ ACT
ProgramsACTengine® is a personalized approach in which the
patient’s own T cells are genetically modified to express a novel
proprietary TCR cognate to one of Immatics’ proprietary cancer
targets which are then reinfused back into the patient. Immatics’
latest proprietary ACTengine® manufacturing processes are designed
to generate cell product candidates within a short six day
manufacturing window and to deliver highly proliferative T cells,
with the capability to infiltrate the patient’s tumor and function
in a challenging solid tumor microenvironment. The process is
designed to rapidly produce younger, better-persisting T cells
capable of “serial” killing tumor cells in vitro. Immatics’ is
further advancing the ACT concept beyond individualized
manufacturing with its product class ACTallo® which is being
developed to generate “off-the-shelf” cellular therapies.
More information on the clinical trials can be
found at the following links:
https://immatics.com/clinical-programs/ and
https://clinicaltrials.gov/.
- ENDS - Notes to Editors
About ImmaticsImmatics combines
the discovery of true targets for cancer immunotherapies with the
development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This
deep know-how is the foundation for our pipeline of Adoptive Cell
Therapies and TCR Bispecifics as well as our partnerships with
global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
For regular updates about Immatics, visit
www.immatics.com. You can also follow us on Twitter and
LinkedIn.
About UTHealthEstablished in
1972 by The University of Texas System Board of Regents, The
University of Texas Health Science Center at Houston (UTHealth) is
Houston’s Health University and Texas’ resource for health care
education, innovation, scientific discovery and excellence in
patient care. The most comprehensive academic health center in the
UT System and the U.S. Gulf Coast region, UTHealth is home to Jane
and Robert Cizik School of Nursing, John P. and Kathrine G.
McGovern Medical School and schools of biomedical informatics,
biomedical sciences, dentistry and public health. UTHealth includes
The University of Texas Harris County Psychiatric Center, as well
as the growing clinical practices UT Physicians, UT Dentists and UT
Health Services. The university’s primary teaching hospitals are
Memorial Hermann-Texas Medical Center, Children’s Memorial Hermann
Hospital and Harris Health Lyndon B. Johnson Hospital. For more
information, visit www.uth.edu.
About the Evelyn H. Griffin Stem Cell
Therapeutics Research LaboratoryThe Evelyn H. Griffin Stem
Cell Therapeutics Research Laboratory, which is part of the
Cellular Therapy Core at UTHealth, has been Immatics’ manufacturing
partner since 2015. The site is a U.S. Food and Drug Administration
(FDA)-registered and inspected cGMP facility that has received
accreditation from the Foundation for Accreditation of Cellular
Therapy (FACT) as well as certification from the Clinical
Laboratory Improvement Amendment (CLIA) and the College of American
Pathologists (CAP).
Forward-Looking
StatementsCertain statements in this press release may be
considered forward-looking statements. Forward-looking statements
generally relate to future events or Immatics’ future financial or
operating performance. For example, statements concerning the
timing of product candidates and Immatics’ focus on partnerships to
advance its strategy are forward-looking statements. In some cases,
you can identify forward-looking statements by terminology such as
“may”, “should”, “expect”, “intend”, “will”, “estimate”,
“anticipate”, “believe”, “predict”, “potential” or “continue”, or
the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks,
uncertainties, and other factors which could cause actual results
to differ materially from those expressed or implied by such
forward looking statements. These forward-looking statements are
based upon estimates and assumptions that, while considered
reasonable by Immatics and its management, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to, various factors beyond management's control including general
economic conditions and other risks, uncertainties and factors set
forth in filings with the Securities and Exchange Commission (SEC).
Nothing in this presentation should be regarded as a representation
by any person that the forward-looking statements set forth herein
will be achieved or that any of the contemplated results of such
forward-looking statements will be achieved. You should not place
undue reliance on forward-looking statements, which speak only as
of the date they are made. Immatics undertakes no duty to update
these forward-looking statements.
- Immatics - UTH Manufacturing Press Release
For more information, please contact:
For Media Inquiries
Gretchen Schweitzer or Jacob Verghese, PhD
Trophic Communications
Phone: +49 89 2388 7731
immatics@trophic.eu
Investor Relations Contact
John Graziano
Solebury Trout
Phone: +1 646 378 2942
jgraziano@soleburytrout.com
Immatics N.V.
Anja Heuer
Corporate Communications
Phone: +49 89 540415-606
media@immatics.com
Jordan Silverstein
Head of Strategy
Phone: +1 281 810 7545
InvestorRelations@immatics.com
UTHealth
Amy Laukka
Sr. Media Relations Specialist
Phone: +1 713-500-3053
Amy.Laukka@uth.tmc.edu
Deborah Lake
Media Relations Director
Phone: +1 713-500-3030
Deborah.M.Lake@uth.tmc.edu
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Apr 2023 to Apr 2024